You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.
Latest Insulin Articles
Popular Insulin Articles
Highly Recommended Insulin Articles
The study shows that a set approach and an ad-hoc approach to bolus dosages both seem to work equally well in achieving glycemic control.
Type 2s who tried out either of two different basal-bolus treatments using Lantus and Apidra enjoyed significant reductions in post-meal BG levels and longer-term A1c’s.
Published in the July 2008 issue of Diabetes Care, those conclusions were based on a study of 273 type 2 patients who were divided into two groups. Both groups used Lantus as their long-acting basal insulin and Apidra as their rapid-acting bolus insulin.
The “Simplified Algorithm” group took pre-set doses of Apidra before their meals. The dosages were based on their self-monitored BG results from the week before.
The “Carbohydrate Counting” group took doses of Apidra based on an insulin-to-carbohydrate ration. They adjusted their doses based on the amount of carbs they planned to consume at a meal.
At the end of the 24-week study, both groups enjoyed similar results: 73 percent of the “Simplified” group and 69 percent of the “Carb Counters” group achieved A1c’s of 7% or less (6.7% for the “Simplifieds” and 6.54% for the “Carb Counters”).
The overall reduction in A1c’s was 1.46% for the “Simplifieds” (down from 8.1%) and 1.59% for the “Carb Counters” (down from 8.3%).
Study participants ranged from 28 to 71 years in age and had had type 2 diabetes for at least six months. Each participant had been taking two or more insulin injections daily for at least three months before the study, and 33 percent of them were also taking metformin.
Thirty-seven percent entered the study using Lantus and at least one daily injection of a rapid-acting insulin analog. Thirty-six percent were using another pre-mixed insulin, and the remainder were on a combination of other diabetes treatment and drug regimens.
Study author Richard M. Bergenstal, MD, executive director of the International Diabetes Center at Park Nicollet Health Services in Minneapolis, Minn., concluded that “a combination of basal and bolus insulin may be needed to achieve optimal glucose control in type 2 diabetes patients.” The study shows that a set approach and an ad-hoc approach to bolus dosages both seem to work equally well in achieving glycemic control.
Categories: A1c Test, Diabetes, Diabetes, Glycemic Index & Carb Counting, Insulin, Lantus, Low Carb, Research, Type 1 Issues, Type 2 Issues
4 comments -
Aug 5, 2008
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.


Email to a Friend
Send a link to this page to your friends and colleagues.